Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ

About

Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	1.17
Market Cap (Mil.):	$243.45
Shares Outstanding (Mil.):	51.04
Dividend:	--
Yield (%):	--

Financials

	PGNX.OQ	Industry	Sector
P/E (TTM):	--	38.69	31.05
EPS (TTM):	-0.88	--	--
ROI:	-42.15	2.39	18.93
ROE:	-52.22	3.60	19.82

Latest News about PGNX.OQ

» More PGNX.OQ News

Competitors

	Price	Change
Takeda Pharmaceutical Company Limited (4502.T)	¥4,340	-80.00
AstraZeneca plc (AZN.L)	3,246.50p	+7.00
Shire PLC (SHP.L)	2,095.00p	+13.00
Shire PLC (3159084.L)	--	--
Cubist Pharmaceuticals Inc (CBST.OQ)	$49.97	-0.20
Algeta ASA (ALGETA.OL)	kr223.90	+1.80
Nektar Therapeutics (NKTR.OQ)	$9.33	+0.06
Medivation Inc (MDVN.OQ)	$47.41	-3.45
Sucampo Pharmaceuticals, Inc. (SCMP.OQ)	$7.30	+0.30
Theravance Inc (THRX.OQ)	$35.41	-0.63

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - PROGENICS PHARMACEUTICALS, INC. (PGNX-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
Market Edge Equity Research Report Provider: Market Edge	$10.00 Buy
Wright Investors Service Comprehensive Report for Progenics Pharmaceuticals, Inc. Provider: Wright Reports	$472.00 Buy
Progenics Pharmaceuticals Provider: S&P Capital IQ Quantitative Report	$69.00 Buy
Progenics Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.